197 related articles for article (PubMed ID: 27539746)
1. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis.
Herac M; Niederle B; Raderer M; Krebs M; Kaserer K; Koperek O
APMIS; 2016 Oct; 124(10):839-45. PubMed ID: 27539746
[TBL] [Abstract][Full Text] [Related]
2. SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival.
de Vries LH; Lodewijk L; Willems SM; Dreijerink KMA; de Keizer B; van Diest PJ; Schepers A; Bonenkamp HJ; van Engen-van Grunsven IACH; Kruijff S; van Hemel BM; Links TP; Nieveen van Dijkum EJM; van Eeden S; Valk GD; Borel Rinkes IHM; Vriens MR
Endocrine; 2018 Dec; 62(3):639-647. PubMed ID: 30128959
[TBL] [Abstract][Full Text] [Related]
3. Clusterin expression in medullary thyroid carcinoma is inversely correlated with the presence of lymph node metastases.
Mourra N; Bennis M; Boelle PY; Cochand-Priollet B; Lefevre M; Lepine C; Balaton A; Klijanienko J; Menegaux F; Tissier F
Hum Pathol; 2017 Jun; 64():37-43. PubMed ID: 28411179
[TBL] [Abstract][Full Text] [Related]
4. Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement.
Aubert S; Berdelou A; Gnemmi V; Behal H; Caiazzo R; D'herbomez M; Pigny P; Wemeau JL; Carnaille B; Renaud F; Bouchindhomme B; Leteurtre E; Perrais M; Pattou F; Do Cao C
Virchows Arch; 2018 Mar; 472(3):461-468. PubMed ID: 29388012
[TBL] [Abstract][Full Text] [Related]
5. Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene.
Koperek O; Bergner O; Pichlhöfer B; Oberndorfer F; Hainfellner JA; Kaserer K; Horvat R; Harris AL; Niederle B; Birner P
J Pathol; 2011 Sep; 225(1):63-72. PubMed ID: 21630273
[TBL] [Abstract][Full Text] [Related]
6. Surgery for lymph node metastases of medullary thyroid carcinoma: A review.
Jin LX; Moley JF
Cancer; 2016 Feb; 122(3):358-66. PubMed ID: 26539937
[TBL] [Abstract][Full Text] [Related]
7. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?
Cho KE; Gweon HM; Park AY; Yoo MR; Kim J; Youk JH; Park YM; Son EJ
Asian Pac J Cancer Prev; 2016; 17(7):3357-62. PubMed ID: 27509975
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological value of somatostatin type 2A and estrogen receptor immunoreactivity in human breast carcinoma.
Pilichowska M; Kimura N; Suzuki A; Yoshida R; Schindler M; Nagura H
Endocr Pathol; 2001; 12(1):55-61. PubMed ID: 11478269
[TBL] [Abstract][Full Text] [Related]
9. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.
Valenciaga A; Grubbs EG; Porter K; Wakely PE; Williams MD; Cote GJ; Vasko VV; Saji M; Ringel MD
Thyroid; 2017 Dec; 27(12):1523-1533. PubMed ID: 29105562
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.
Papotti M; Kumar U; Volante M; Pecchioni C; Patel YC
Clin Endocrinol (Oxf); 2001 May; 54(5):641-9. PubMed ID: 11380495
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues.
Kunikowska J; Ziemnicka K; Pawlak D; Ruchała M; Kolasa A; Janicka-Jedyńska M; Woźniak A; Mikołajczak R; Królicki L
Endokrynol Pol; 2016; 67(1):68-71. PubMed ID: 26884118
[TBL] [Abstract][Full Text] [Related]
12. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
14. Breach of the thyroid capsule and lymph node capsule in node-positive papillary and medullary thyroid cancer: Different biology.
Machens A; Dralle H
Eur J Surg Oncol; 2015 Jun; 41(6):766-72. PubMed ID: 25468749
[TBL] [Abstract][Full Text] [Related]
15. Abandoning node dissection for desmoplasia-negative encapsulated unifocal sporadic medullary thyroid cancer.
Machens A; Kaatzsch P; Lorenz K; Horn LC; Wickenhauser C; Schmid KW; Dralle H; Siebolts U
Surgery; 2022 Feb; 171(2):360-367. PubMed ID: 34602296
[TBL] [Abstract][Full Text] [Related]
16. Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
Br J Surg; 2019 Mar; 106(4):412-418. PubMed ID: 30725475
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.
Kendler DB; Araújo ML; Alencar R; de Souza Accioly MT; Bulzico DA; de Noronha Pessoa CC; Accioly FA; de Farias TP; Lopes FPPL; Corbo R; Vaisman M; Vaisman F
Endocrine; 2017 Dec; 58(3):474-480. PubMed ID: 28948577
[TBL] [Abstract][Full Text] [Related]
18. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
Giardino E; Catalano R; Mangili F; Barbieri AM; Treppiedi D; Elli FM; Dolci A; Contarino A; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2021 Jan; 520():111092. PubMed ID: 33248230
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathological and prognostic findings on 27 cases of medullary thyroid carcinoma.
Gabsi A; El Amine El Hadj O; Goucha A; Said G; Laabidi B; Gamoudi A
Tunis Med; 2017 Feb; 95(2):97-102. PubMed ID: 29424867
[TBL] [Abstract][Full Text] [Related]
20. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
Xu B; Fuchs TL; Ahmadi S; Alghamdi M; Alzumaili B; Bani MA; Baudin E; Chou A; De Leo A; Fagin JA; Ganly I; Glover A; Hartl D; Kanaan C; Khneisser P; Najdawi F; Nigam A; Papachristos A; Repaci A; Spanheimer PM; Solaroli E; Untch BR; Barletta JA; Tallini G; Al Ghuzlan A; Gill AJ; Ghossein RA
J Clin Oncol; 2022 Jan; 40(1):96-104. PubMed ID: 34731032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
